FDA clears breast biopsy device

Article

Advanced Imaging Technologies has received marketing clearance from the FDA for a breast biopsy on its Avera Breast Imaging System. Unlike conventional ultrasound scanners, Avera uses diffractive, or "through-wave," ultrasound. The biopsy capability will

Advanced Imaging Technologies has received marketing clearance from the FDA for a breast biopsy on its Avera Breast Imaging System. Unlike conventional ultrasound scanners, Avera uses diffractive, or "through-wave," ultrasound. The biopsy capability will allow physicians to perform immediate biopsies on suspicious breast masses during an Avera imaging session, according to the company.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Can the Emerging InteleHeart Platform Facilitate Improved Efficiency with Cardiology and Radiology?
Diagnostic Imaging’s Weekly Scan: October 5 — October 11
Current Insights on Interoperability, Enterprise Imaging and AI Integration in Radiology
© 2025 MJH Life Sciences

All rights reserved.